U.S. Markets open in 6 hrs 35 mins

Atlanta's MiMedx sued by competitor Osiris Therapeutics for alleged 'deceit, trickery, and unfair methods'

David Allison
Atlanta's MiMedx sued by competitor Osiris Therapeutics for alleged 'deceit, trickery, and unfair methods'

Troubled Atlanta biomedical company MiMedx Group Inc. (OTC: MDXG) is being sued by competitor Osiris Therapeutics Inc. (Nasdaq: OSIR), who claims MiMedx "jeopardized Osiris’s business by deceit, trickery, and unfair methods." In a complaint filed Feb. 20 in federal court in Atlanta, Columbia, Md.-based Osiris contends MiMedx and a distributor it formerly owned, Stability Biologics, breached several obligations they owed to Osiris, which had been a customer of Stability before it was bought by MiMedx in January 2016. Osiris and MiMedx are direct competitors in the market for regenerative cellular and tissue-based products used to treat injuries and wounds.